Home
Par Pharmaceutical

Par Pharmaceutical Market Share Analysis for November 2025

Health > Biotechnology and Pharmaceuticals

Domainparpharm.com

Year Founded1978

Employees501 - 1000

Annual Revenue$200M - $500M

Par Pharmaceutical

Par Pharmaceutical (including company regionals)

parpharm.com

See more website traffic and engagement information

Par Pharmaceutical Revenue up to November 2025 is 200M - 500M

revenue generated by Par Pharmaceutical top domains

Par Pharmaceutical top domains revenue over 3 years

Revenue for Par Pharmaceutical top domains

parpharm.com200M - 500M

See more with Sales Intelligence

Total visits to Par Pharmaceutical's top domains

Understand Par Pharmaceutical market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Par Pharmaceutical's top domains

Analyze Par Pharmaceutical engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Par Pharmaceutical's top domains

See how Par Pharmaceutical keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Par Pharmaceutical top competitors by domain

Top similar sites in November 2025, ranked by their affinity

tevapharm.comCompany NameTeva PharmaceuticalsEmployees> 10001HQIsrael, Tel AvivAnnual revenue> $1BTotal visits1.3MHealth > Biotechnology and Pharmaceuticals

Top technologies used by Par Pharmaceutical

These are the website technologies, by industry, used by Par Pharmaceutical top domains

Conversion & Analytics (3)

Google Analytics

Advertising (2)

DoubleClick

Content Management System (2)

Web Dot Com

Marketing (2)

Google Marketing Platform

More Technologies

5

See all

News & Signals from Par Pharmaceutical

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsParpharm has issues with recall of one lot of treprostinil.Par Pharmaceutical, a subsidiary of Endo International, announced a voluntary recall of one lot of treprostinil injection 20mg/20mL due to the potential for the presence of silicone particulates in the product solution.

NewsParpharm launches ibuprofen-famotidine 800 mg/26.6 mg tablets.DUBLIN, March 26, 2024 /PRNewswire/ - Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS(R).

NewsParpharm launched generic version of the medication DUEXIS on Feb 26th '24.DUBLIN - Endo International plc (OTC: OTC:ENDPQ) through its subsidiary Par Pharmaceutical, Inc., has recently launched a generic version of the medication DUEXIS(R), which combines ibuprofen and famotidine.